Alethia Young
Stock Analyst at Cantor Fitzgerald
(2.97)
# 546
Out of 4,829 analysts
141
Total ratings
51.11%
Success rate
47.65%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $8.80 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $13.97 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $575.63 | +47.66% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $0.44 | +4,036.03% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $1.96 | +2,961.22% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $2.87 | +213.59% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $7.29 | +366.39% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $124.40 | +162.86% | 7 | Oct 15, 2021 | |
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $230 → $30 | $2.71 | +1,007.01% | 4 | Jul 23, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $51 → $71 | $0.88 | +7,979.20% | 2 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $281 | $439.37 | -36.04% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $2.43 | +229.22% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.07 | +9,058.88% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $274.76 | +7.37% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $103.82 | -17.16% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $34.99 | +37.18% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $8.60 | +248.84% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $29.14 | +147.08% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.10 | +354.55% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $60.85 | +64.34% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $154.43 | +30.16% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $46.01 | +84.74% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $8.12 | +294.09% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $36.37 | +496.65% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $20.03 | +139.64% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $11.35 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $270.19 | -43.00% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $61.37 | +89.02% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $3.04 | +3,386.84% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $8.55 | +227.49% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $203.85 | -59.77% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $310.80 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.63 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.80
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.97
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $575.63
Upside: +47.66%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $0.44
Upside: +4,036.03%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $1.96
Upside: +2,961.22%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $2.87
Upside: +213.59%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $7.29
Upside: +366.39%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $124.40
Upside: +162.86%
Adverum Biotechnologies
Jul 23, 2021
Downgrades: Neutral
Price Target: $230 → $30
Current: $2.71
Upside: +1,007.01%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $51 → $71
Current: $0.88
Upside: +7,979.20%
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $439.37
Upside: -36.04%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $2.43
Upside: +229.22%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.07
Upside: +9,058.88%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $274.76
Upside: +7.37%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $103.82
Upside: -17.16%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $34.99
Upside: +37.18%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $8.60
Upside: +248.84%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $29.14
Upside: +147.08%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.10
Upside: +354.55%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $60.85
Upside: +64.34%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $154.43
Upside: +30.16%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $46.01
Upside: +84.74%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $8.12
Upside: +294.09%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $36.37
Upside: +496.65%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $20.03
Upside: +139.64%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $11.35
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $270.19
Upside: -43.00%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $61.37
Upside: +89.02%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $3.04
Upside: +3,386.84%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $8.55
Upside: +227.49%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $203.85
Upside: -59.77%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $310.80
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $1.63
Upside: -